newsfilter
← Latest News
Business Wire·

Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results

Completion of recruitment for pivotal Phase 3 LUCIDITY trial of avexitide expected in Q1 2026, with topline data anticipated in Q3 2026 Cash runway expected into 2028, through the potential approval and commercial